Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126909 | 0.87 | ELANE (0.57) | ELANENOTUMKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL984085 | 0.87 | NOTUM (0.64) | ELANENOTUMCYP1A2POLBLMNA | |
| SCHEMBL8229059 | 0.86 | NOTUM (0.51) | ELANENOTUMKDM4ECYP1A2BRD9 | |
| SCHEMBL4152986 | 0.86 | ELANE (0.50) | ELANENOTUMCYP1A2CCR1LMNA | |
| SCHEMBL4137643 | 0.86 | PDE4B (0.50) | ELANENOTUMSMN1; SMN2 | |
| SCHEMBL27716691 | 0.86 | NOTUM (0.53) | ELANENOTUMCYP1A2POLBLMNA | |
| SCHEMBL8053624 | 0.84 | ELANE (0.49) | ELANENOTUMKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL27643868 | 0.84 | ELANE (0.57) | ELANENOTUMCCR1 | |
| SCHEMBL560875 | 0.83 | ELANE (0.77) | ELANE | |
| SCHEMBL1604233 | 0.83 | KDM4E (0.49) | ELANENOTUMKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998984-B2 | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2011-08-16 | — | — | US | disclosed |
| EP-2018375-B1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| US-20090131486-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131486-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, SERPINB6 | ELANE 2/4885NOTUM 3441/4885KDM4E 3112/4885 |
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | ELANE 2/4885NOTUM 2654/4885KDM4E 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.